Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 1
1994 5
1996 1
1997 3
1998 3
1999 8
2000 9
2001 4
2002 10
2003 7
2004 11
2005 13
2006 19
2007 47
2008 53
2009 57
2010 88
2011 83
2012 106
2013 121
2014 119
2015 135
2016 176
2017 159
2018 146
2019 129
2020 117
2021 164
2022 132
2023 117
2024 119
2025 128
2026 63

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,084 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, Cohen K, Schotte A, Milz R, Venkatasubramanian R, T'Jollyn H, Walling DP, Galderisi S, Gopal S. Najarian D, et al. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238-251. doi: 10.1093/ijnp/pyab071. Int J Neuropsychopharmacol. 2022. PMID: 34791283 Free PMC article. Clinical Trial.
BACKGROUND: This double-blind (DB), randomized, parallel-group study was designed to evaluate efficacy and safety of paliperidone palmitate 6-month (PP6M) formulation relative to paliperidone palmitate 3-month (PP3M) formulation in patients with schizo …
BACKGROUND: This double-blind (DB), randomized, parallel-group study was designed to evaluate efficacy and safety of paliperidone …
Paliperidone for schizophrenia.
Dolder C, Nelson M, Deyo Z. Dolder C, et al. Am J Health Syst Pharm. 2008 Mar 1;65(5):403-13. doi: 10.2146/ajhp070261. Am J Health Syst Pharm. 2008. PMID: 18281731 Review.
Paliperidone's advanced-generation osmotic release delivery system allows for the avoidance of dosage adjustment when initiating therapy and may decrease the frequency of antido-paminergic effects that would occur with an immediate-release formulation. The pharmacol …
Paliperidone's advanced-generation osmotic release delivery system allows for the avoidance of dosage adjustment when initiati …
Paliperidone and Edema.
Frankenburg FR, Malvesti S. Frankenburg FR, et al. J Clin Psychopharmacol. 2022 Mar-Apr 01;42(2):225-226. doi: 10.1097/JCP.0000000000001429. J Clin Psychopharmacol. 2022. PMID: 34176871 No abstract available.
Paliperidone-Induced Hyponatremia.
Tibrewal P, Dhillon R, Sharma J, Bastiampillai T. Tibrewal P, et al. Prim Care Companion CNS Disord. 2017 Jul 27;19(4):16l02088. doi: 10.4088/PCC.16l02088. Prim Care Companion CNS Disord. 2017. PMID: 28767207 Free article. No abstract available.
[Paliperidone].
Oberpichler-Schwenk H. Oberpichler-Schwenk H. Med Monatsschr Pharm. 2006 Aug;29(8):280-2. Med Monatsschr Pharm. 2006. PMID: 16927595 German. No abstract available.
Paliperidone for the treatment of schizoaffective disorder.
Alphs L, Fu DJ, Turkoz I. Alphs L, et al. Expert Opin Pharmacother. 2016;17(6):871-83. doi: 10.1517/14656566.2016.1161029. Epub 2016 Mar 24. Expert Opin Pharmacother. 2016. PMID: 26934062 Review.
AREAS COVERED: Data from 3 pivotal studies evaluating the acute and maintenance treatment of SCA with paliperidone are reviewed. Two formulations of paliperidone have been studied for these indications: an extended-release oral formulation (NCT00397033, NCT00412373) …
AREAS COVERED: Data from 3 pivotal studies evaluating the acute and maintenance treatment of SCA with paliperidone are reviewed. Two …
The preclinical discovery and development of paliperidone for the treatment of schizophrenia.
Wesołowska A, Jastrzębska-Więsek M, Cios A, Partyka A. Wesołowska A, et al. Expert Opin Drug Discov. 2020 Mar;15(3):279-292. doi: 10.1080/17460441.2020.1682994. Epub 2019 Oct 29. Expert Opin Drug Discov. 2020. PMID: 31661992 Review.
It is recommended in patients with hepatic impairment and evokes less drug-drug interactions.Areas covered: This review article focuses on the preclinical discovery of paliperidone, the major active metabolite of risperidone. It provides details regarding paliperidone …
It is recommended in patients with hepatic impairment and evokes less drug-drug interactions.Areas covered: This review article focuses on t …
Paliperidone-associated motor tics.
Hsieh MH, Chiu NY. Hsieh MH, et al. Gen Hosp Psychiatry. 2014 May-Jun;36(3):360.e7-8. doi: 10.1016/j.genhosppsych.2014.01.003. Epub 2014 Jan 14. Gen Hosp Psychiatry. 2014. PMID: 24556260
OBJECTIVES: Paliperidone-associated motor tics. METHOD: Case report. RESULTS: We report a 30-year-old man with schizophrenia who developed motor tics (eye blinking) after treatment of paliperidone up to 15 mg daily. CONCLUSION: Tic-like symptoms, from simple eye bli …
OBJECTIVES: Paliperidone-associated motor tics. METHOD: Case report. RESULTS: We report a 30-year-old man with schizophrenia who deve …
Intramuscular paliperidone palmitate.
Hoy SM, Scott LJ, Keating GM. Hoy SM, et al. CNS Drugs. 2010 Mar;24(3):227-44. doi: 10.2165/11203810-000000000-00000. CNS Drugs. 2010. PMID: 20155997
Intramuscular paliperidone palmitate is a long-acting, atypical antipsychotic that is indicated in the US for the acute and maintenance therapy of adult patients with schizophrenia. ...Intramuscular paliperidone palmitate 39-234 mg was generally well t …
Intramuscular paliperidone palmitate is a long-acting, atypical antipsychotic that is indicated in the US for the acute and ma …
A review of paliperidone palmitate.
Chue P, Chue J. Chue P, et al. Expert Rev Neurother. 2012 Dec;12(12):1383-97. doi: 10.1586/ern.12.137. Expert Rev Neurother. 2012. PMID: 23237346 Review.
Paliperidone long-acting injection (PLAI) has now been developed as a suspension of paliperidone palmitate nanocrystals in an aqueous formulation (Invega Sustenna , Xeplion ), administered monthly by intramuscular injection (deltoid or gluteal). Doses of PLAI …
Paliperidone long-acting injection (PLAI) has now been developed as a suspension of paliperidone palmitate nanocrystals …
2,084 results